Skip to content
HowShorted

ROCKET PHARMACEUTICALS, INC. short interest in 2020

In 2020, ROCKET PHARMACEUTICALS, INC.'s disclosed short interest ran from 14.53% of shares outstanding on 15 Jan 2020 to 14.90% on 31 Dec 2020, a change of +0.37 percentage points. The year's high was 17.58% on 30 Oct 2020 and its low 13.73% on 13 Mar 2020, averaging 15.73% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 48.90 days on 15 Sep 2020. Full history: ROCKET PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for ROCKET PHARMACEUTICALS, INC. in 2020

2020 in figures

Start of year
14.53% (15 Jan 2020)
End of year
14.90% (31 Dec 2020)
Change
+0.37 pp
High
17.58% (30 Oct 2020)
Low
13.73% (13 Mar 2020)
Average
15.73%
Highest days to cover
48.90 (15 Sep 2020)
SEC filings marked
4

Every report in 2020

ROCKET PHARMACEUTICALS, INC. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202014.53%19.63
31 Jan 202013.99%25.90
14 Feb 202014.16%22.35
28 Feb 202014.10%19.66
13 Mar 202013.73%14.1310-K filed
31 Mar 202014.02%16.96
15 Apr 202015.02%21.33
30 Apr 202014.74%22.54
15 May 202014.81%22.6910-Q filed
29 May 202015.22%34.45
15 Jun 202015.05%27.22
30 Jun 202016.03%14.06
15 Jul 202016.76%18.65
31 Jul 202016.81%26.46
14 Aug 202017.22%31.1810-Q filed
31 Aug 202017.16%46.65
15 Sep 202017.23%48.90
30 Sep 202017.32%37.46
15 Oct 202017.47%33.22
30 Oct 202017.58%39.60
13 Nov 202016.56%30.9010-Q filed
30 Nov 202016.46%22.01
15 Dec 202016.71%5.54
31 Dec 202014.90%11.79

See also: ROCKET PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.